Investigational drug · Phase 3
APG-157
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of the Oropharynx.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
5
Any phase or sponsor naming "APG-157"
First trial start
2022
Apr 22, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "APG-157", any sponsor or status.
Conditions studied
As listed on its trial records.
- Head and Neck Cancer
- Squamous Cell Carcinoma of Oral Cavity
- Squamous Cell Carcinoma of the Oropharynx
- Head and Neck (HNSCC)
- Oropharyngeal
- Oral Cavity
- Oral Cavity Carcinoma
- Oropharynx Squamous Cell Carcinoma
- Oral Cavity Squamous Cell Carcinoma
- Glioma
Approved drugs for the same conditions: Head and neck cancer · Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "APG-157" as an intervention, largest first.
- APG-157 in Locally Advanced Head and Neck Squamous Cell CarcinomaPivotal-lookingNot yet recruiting
Aveta Biomics, Inc.Industry
NCT07667296 · 826 participants (planned) · Start Jul 2026 · Primary completion Dec 2031
Drug: APG-157 · For: Head and Neck Cancer; Head and Neck (HNSCC); Oropharyngeal and 4 more
Elizabeth J FranzmannAcademic, hospital or other
NCT05865028 · 32 participants (planned) · Start May 24, 2023 · Primary completion May 24, 2027
Drug: APG-157 · For: Oropharyngeal Dysplasia; Oral Cavity Dysplasia; Oral Carcinoma in Situ
Sites: Miami, Florida
- Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and BevacizumabActive, not recruiting
Aveta Biomics, Inc.Industry
NCT06011109 · 30 participants (planned) · Start Dec 13, 2023 · Primary completion Dec 31, 2026
Drug: APG-157 · For: Glioma; Glioblastoma Multiforme
Sites: Rochester, Minnesota; Omaha, Nebraska
- Safety and Efficacy of APG-157 in Head and Neck CancerActive, not recruiting
Aveta Biomics, Inc.Industry
NCT05312710 · 24 participants (planned) · Start Apr 22, 2022 · Primary completion Dec 2026
Drug: APG-157 · For: Head and Neck Cancer; Squamous Cell Carcinoma of Oral Cavity; Squamous Cell Carcinoma of the Oropharynx
Sites: Los Angeles, California; Miami, Florida
- Treatment of Recurrent GBM With APG-157 Via Expanded AccessNo longer available
Aveta Biomics, Inc.Industry
NCT05551013
Drug: APG-157 · For: Glioblastoma; Glioblastoma Multiforme
Newest research
PubMed records naming it or its code names, newest first.
- Role of curcumin and its nanoformulations in the management of oral squamous cell carcinoma: A systematic review.
Minervini G, Rajkumar C, Veeraraghavan VP, et al. · Dent Med Probl 2026
- Enhanced CTLA-4 blockade anti-tumor immunity with APG-157 combination in a murine head and neck cancer.
Shin DS, Basak S, Veena MS, et al. · Cancer Med 2024
- Cell-Free RNA as a Novel Biomarker for Response to Therapy in Head & Neck Cancer.
Tosevska A, Morselli M, Basak SK, et al. · Front Oncol 2022
- A randomized, phase 1, placebo-controlled trial of APG-157 in oral cancer demonstrates systemic absorption and an inhibitory effect on cytokines and tumor-associated microbes.
Basak SK, Bera A, Yoon AJ, et al. · Cancer 2020
Also in development for Head and Neck Cancer
- SurzebiclimabBGB-A425Phase 33 trials
BeOne Medicines (BeiGene) · Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion, NSCLC for Phase 2 Dose Expansion
- Buparlisib & PaclitaxelAN2025Phase 31 trial
Adlai Nortye Biopharma Co., Ltd. · Head and Neck Cancer
- EvorpaceptALX148Phase 25 trials
ALX Oncology Inc. · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Metastatic
- BT5528nuzefatide pevedotinPhase 23 trials
BicycleTx Limited · Advanced Solid Tumors, Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer
- INCAGN02385Phase 23 trials
Incyte · Melanoma, Endometrial Cancer, Head and Neck Cancer
- INCAGN02390Phase 23 trials
Incyte · Melanoma, Endometrial Cancer, Head and Neck Cancer
- MCLA-129Phase 23 trials
Betta Pharmaceuticals Co., Ltd. · Non-Small Cell Lung Cancer, Solid Tumor, Head and Neck Cancer
- Carboplatin AUC-5Phase 22 trials
Inhibrx Biosciences, Inc · Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.